What is NTRA's market cap?

$56.36B, based on the Nov 4 close of $391.03.

Does Natera pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NTRA is sold short?

5.9M shares, 4.3% of float, as of Oct 15, 2026.

What sector is NTRA in?

Healthcare, in the Medical Labs industry.

NASDAQ · NTRAHealthcareMedical Labs

Natera, Inc. Common Stock (NTRA)

$391.03+0.62%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$391.03▲ 99.05% in range

Nov 4, 2025Low $182.65 · High $436.00Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Natera closed at $391.03 on Nov 4, up 0.62%, 10.3% below its 52-week closing high. Volume of 2.8M shares was 1.67× its 20-day average (above normal).

Split-adjusted performance: -2.4% over one month, +81.8% over six months, +97.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $752.75M, up 37.7% from a year earlier, with a net margin of -8.9%.

Short interest was 5.9M shares at the Oct 15 settlement, down 7.9% from the prior report (4.3% of float, 3.4 days to cover).

Market cap$56.36B144.1M shares

Revenue · quarter$752.8M+37.7% YoY

Diluted EPS$-0.47—

P/E · TTM—P/S 20.8×

Net margin-8.9%Gross 64.5%

Dividend yieldNone

52-week range182.65 – 436.00−10.3% from high

Volume2.8M1.67× 20-day avg

Volatility · 60d40.5%Annualised

Short % of float4.3%3.4 days to cover

Net cash$1.01BCash $1.09B

Next earnings—Not scheduled

Split-adjusted performance

1W −7.9%1M −2.4%3M +47.3%6M +81.8%YTD +70.7%1Y +97.3%3Y +941.4%5Y +243.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum77

Revenue growth78

Net margin43

Value (low P/E)—

Size100

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →

Shares short5.9M−7.9% vs prior

Days to cover3.4Settled Oct 15

% of float4.3%

Short vol. 10d42.6%of daily volume

Closest peers by size in Medical Labs

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NTRANatera	$391.03	+0.62%	+81.8%	+37.7%	−8.9%	—	$56.36B
LHLabcorp Holdings	$367.79	+3.92%	+43.1%	+6.9%	6.9%	29.7	$29.86B	Compare
DGXQuest Diagnostics	$255.68	+3.49%	+35.2%	+10.0%	10.0%	25.1	$28.22B	Compare
GHGuardant Health	$168.58	−3.67%	+82.7%	+44.3%	−35.9%	—	$22.62B	Compare
CAICaris Life Sciences	$33.22	+1.13%	+73.7%	+45.4%	−0.2%	89.3	$9.39B	Compare
GRALGRAIL	$143.66	+3.03%	+128.9%	+25.7%	−246.7%	—	$6.42B	Compare
RDNTRadNet	$80.26	+9.67%	+36.9%	+25.0%	1.2%	—	$6.32B	Compare
BLLNBillionToOne	$113.89	+3.11%	+39.9%	—	7.4%	—	$5.37B	Compare
CDNACareDx	$85.86	−2.95%	+309.8%	+39.3%	13.8%	35.1	$4.51B	Compare

News about Natera

All news →

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?Zacks Investment Research · Oct 28, 2026▼ Negative Natera Partners With TransCode to Advance Colorectal Cancer TrialZacks Investment Research · Oct 21, 2026▲ Positive Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDxZacks Investment Research · Sep 23, 2026▲ Positive Natera Positioned To Capture Growing $20 Billion MRD Opportunity-AnalystBenzinga · Apr 14, 2026▲ Positive Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip SurgeryBenzinga · Mar 31, 2026▲ Positive

Quick answers

What does Natera do?: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
What is NTRA's market cap?: $56.36B, based on the Nov 4 close of $391.03.
Does Natera pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NTRA is sold short?: 5.9M shares, 4.3% of float, as of Oct 15, 2026.
What sector is NTRA in?: Healthcare, in the Medical Labs industry.

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

HQ: Austin, TX6,140 employeesListed Jul 2, 2015natera.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology